GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

GSK to resolve 93% of US state court Zantac product liability cases for up to $2.2 billion: London, UK Friday, October 11, 2024, 14:00 Hrs [IST] GSK plc announced that it has reac ...

GSK's $2.2bn payment to settle 93% of outstanding Zantac lawsuits in the US was close to the "best case scenario", according ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...

GSK (LSE: GSK) has settled 93% of Zantac (ranitidine) product liability cases in the USA, agreeing to pay up to $2.2 billion ...

Pharmaceutical giant GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle most of lawsuits filed in U.S.

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...